PVLA vs. ZYME
PVLA (Palvella Therapeutics, Inc) and ZYME (Zymeworks Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past year, PVLA returned 426.53% vs 91.50% for ZYME. At a 0.30 correlation, their price movements are largely independent.
Performance
PVLA vs. ZYME - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, PVLA achieves a 13.38% return, which is significantly higher than ZYME's -9.30% return.
PVLA
- 1D
- -0.13%
- 1M
- 4.11%
- YTD
- 13.38%
- 6M
- 18.36%
- 1Y
- 426.53%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
ZYME
- 1D
- 2.67%
- 1M
- -6.76%
- YTD
- -9.30%
- 6M
- -10.86%
- 1Y
- 91.50%
- 3Y*
- 43.33%
- 5Y*
- -8.24%
- 10Y*
- —
PVLA vs. ZYME - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | |
|---|---|---|---|
PVLA Palvella Therapeutics, Inc | 13.38% | 772.25% | -8.27% |
ZYME Zymeworks Inc. | -9.30% | 79.85% | 16.38% |
Correlation
The correlation between PVLA and ZYME is 0.34, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.34 |
Correlation (All Time) Calculated using the full available price history since Dec 16, 2024 | 0.30 |
Fundamentals
PVLA:
$1.34B
ZYME:
$1.78B
PVLA:
-$3.75
ZYME:
-$583.41
PVLA:
47.72
ZYME:
0.01
PVLA:
$0.00
ZYME:
$78.86M
PVLA:
$0.00
ZYME:
$77.16M
PVLA:
-$14.75M
ZYME:
-$47.18B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
PVLA vs. ZYME — Risk / Return Rank
PVLA
ZYME
PVLA vs. ZYME - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Palvella Therapeutics, Inc (PVLA) and Zymeworks Inc. (ZYME). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| PVLA | ZYME | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +3.58 | ||
| Sortino ratioReturn per unit of downside risk | +1.78 | ||
| Omega ratioGain probability vs. loss probability | 1.54 | 1.33 | +0.21 |
| Calmar ratioReturn relative to maximum drawdown | 13.82 | 4.33 | +9.49 |
| Martin ratioReturn relative to average drawdown | 31.14 | 9.21 | +21.94 |
Loading charts...
Drawdowns
PVLA vs. ZYME - Drawdown Comparison
The maximum PVLA drawdown since its inception was -31.48%, smaller than the maximum ZYME drawdown of -91.81%. Use the drawdown chart below to compare losses from any high point for PVLA and ZYME.
Loading charts...
Drawdown Indicators
| PVLA | ZYME | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -31.48% | -91.81% | +60.33% |
Max Drawdown (1Y)Largest decline over 1 year | -31.11% | -21.25% | -9.86% |
Max Drawdown (3Y)Largest decline over 3 years | — | -45.75% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -87.53% | — |
Current DrawdownCurrent decline from peak | -19.99% | -57.97% | +37.98% |
Average DrawdownAverage peak-to-trough decline | -11.16% | -52.54% | +41.38% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 13.79% | 9.97% | +3.82% |
Volatility
PVLA vs. ZYME - Volatility Comparison
Palvella Therapeutics, Inc (PVLA) has a higher volatility of 19.68% compared to Zymeworks Inc. (ZYME) at 10.12%. This indicates that PVLA's price experiences larger fluctuations and is considered to be riskier than ZYME based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| PVLA | ZYME | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 19.68% | 10.12% | +9.56% |
Volatility (6M)Calculated over the trailing 6-month period | 61.91% | 29.45% | +32.46% |
Volatility (1Y)Calculated over the trailing 1-year period | 80.85% | 52.91% | +27.94% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 82.11% | 61.85% | +20.26% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 82.11% | 61.45% | +20.66% |
Dividends
PVLA vs. ZYME - Dividend Comparison
Neither PVLA nor ZYME has paid dividends to shareholders.
Financials
PVLA vs. ZYME - Financials Comparison
This section allows you to compare key financial metrics between Palvella Therapeutics, Inc and Zymeworks Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
PVLA and ZYME have a correlation of 0.34, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
PVLA has higher volatility (19.68%) compared to ZYME (10.12%). In terms of maximum drawdown, PVLA dropped -31.48% vs ZYME's -91.81%.
PVLA currently has the higher Sharpe Ratio (5.32 vs 1.74), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for PVLA and ZYME
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer